QIN-PROSTATE-Repeatability

Summary

 This is a dataset with multiparametric MRI protocol applied in a test-retest setting, allowing to evaluate repeatability of the MRI-based measurements in the prostate. There is very limited data about the repeatability in mpMRI of the prostate, while such information is critical for imaging biomarker development. Data was provided by Brigham and Women's Hospital, PI Dr. Fiona Fennessy.Type of cancer: Confirmed or suspected prostate cancer

Acquisition Protocol: Standard prostate mpMRI protocol implemented at our institution was used in this study. For a given patient, we aimed to maintain similar protocol settings, and used the same scanner hardware and software configurations for both the baseline and repeat examinations, which were acquired within 2 weeks of time. Due to the scanner hardware upgrade in the middle of the study, 6 of the patients had baseline and repeat study performed on a GE Signa HDxt platform, software release 15.0_M4A_097.a, while the remaining 7 patients were scanned on a GE Discovery MR750w, software release DV24.0_R01_1344 (General Electric Healthcare, Milwaukee, WI). Transrectal coil within an air-filled balloon (Medrad Inc., Warrendale, PA) was used in all imaging studies. mpMRI protocol included T2-weighted, Diffusion Weighted (DW) (b-values of 0 and 1400 mm/s2) and Dynamic Contrast Enhanced (DCE) sequences. Detailed acquisition parameters are listed in Table 1. DWI Apparent Diffusion Coefficient (ADC) and DCE subtract maps (further referred to as SUB; computed as the difference between the phase corresponding to the contrast bolus arrival and the baseline phase) were generated using the scanner software. In the initial submission, we plan to only include imaging data (in DICOM) and segmentations (in DICOM). We subsequently plan to augment this dataset with more imaging data (that one requires specialized analysis, which we don't do for the current publication), parametric maps obtained using that analysis (in DICOM), and potentially (pending IRB clearance) clinical data (demographics, PSA) and pathology sampling data (biopsy Gleason score).

Publications:

About the NCI QIN

The mission of the QIN is to improve the role of quantitative imaging for clinical decision making in oncology by developing and validating data acquisition, analysis methods, and tools to tailor treatment for individual patients and predict or monitor the response to drug or radiation therapy. More information is available on the Quantitative Imaging Network Collections page. Interested investigators can apply to the QIN at: Quantitative Imaging for Evaluation of Responses to Cancer Therapies (U01) PAR-11-150.